Clinical Trial

A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to estimate the relative bioavailability of UCB0022 Formulation 2 (Test) versus Formulation 1 (Reference) in healthy participants following single oral administration.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-10-22; most recent amendment 2026-01-05.
Status change: Active, Not Recruiting → Completed 2025-12-18
Status change: Recruiting → Active, Not Recruiting 2025-12-03
Status change: Not Yet Recruiting → Recruiting 2025-10-27
Trial Details
NCT Number NCT07220551
Lead Sponsor UCB Biopharma SRL
Conditions Healthy Volunteers
Enrollment 14 participants
Start Date 2025-10-23
Primary Completion 2025-12-16 (estimated)
Study Completion 2025-12-16 (estimated)
Updated on ClinicalTrials.gov 2026-01-06